Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Analysts

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $99.1111.

Several equities analysts have recently commented on GPCR shares. Stifel Nicolaus upped their price target on shares of Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Structure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Citigroup reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Friday, December 12th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Structure Therapeutics in a research report on Tuesday, January 6th.

Structure Therapeutics Trading Up 4.3%

Shares of Structure Therapeutics stock opened at $88.64 on Monday. The stock has a market capitalization of $5.38 billion, a price-to-earnings ratio of -72.66 and a beta of -2.05. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $94.90. The business’s 50 day simple moving average is $55.31 and its 200-day simple moving average is $34.24.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). Sell-side analysts predict that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Investors Weigh In On Structure Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. State of Wyoming bought a new position in Structure Therapeutics in the 2nd quarter valued at about $28,000. EverSource Wealth Advisors LLC raised its position in shares of Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after buying an additional 901 shares in the last quarter. Assetmark Inc. lifted its stake in shares of Structure Therapeutics by 39.9% in the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after acquiring an additional 820 shares during the period. PNC Financial Services Group Inc. boosted its holdings in shares of Structure Therapeutics by 29.1% in the second quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after acquiring an additional 994 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd increased its stake in shares of Structure Therapeutics by 39.1% during the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after acquiring an additional 1,146 shares during the period. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.